Filing Details

Accession Number:
0000950170-24-011400
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-05 18:13:07
Reporting Period:
2024-02-01
Accepted Time:
2024-02-05 18:13:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1521548 Michael Halstead C/O Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Evp And General Counsel No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-01 11,860 $0.00 11,860 No 4 A Direct
Common Stock Disposition 2024-02-02 11,146 $66.37 714 No 4 S Direct
Common Stock Disposition 2024-02-02 714 $67.17 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents shares issued upon the vesting of performance stock units.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 15, 2023 and amended on May 8, 2023 and August 11, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.02 to $67.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $67.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.